January 24, 2014

BBSRC chief executive Douglas Kell highlights Exscientia approach for advancement of complex drug design

Douglas Kell CBE, Chief Executive of the Biological and Biotechnology Scientific Research Council (BBSRC) identifies Nature paper as an important contribution to systems based approaches to polypharmacology. Professor Kell drew attention to the work in response to the Nature SciBX article in his BBSRC blog and a subsequent interviews with reporters. He said: "This new automated, adaptive methodology by Dundee mimics the design process of human chemists but runs it on a very large scale at a faster rate. This technology could make significant advances in discovering and designing complex drugs."
See earlier blog here: http://blogs.bbsrc.ac.uk/index.php/2012/12/council-rothamsted-gsk-and-climate-change/

Liked the article? Let’s share it!